J Breast Cancer.  2012 Jun;15(2):218-223. 10.4048/jbc.2012.15.2.218.

The Risk Factors Influencing between the Early and Late Recurrence in Systemic Recurrent Breast Cancer

• Song WJ
• Kim KI
• Park SH
• Kwon MS
• Lee TH
• Park HK
• An JS

• KMID: 2242193
• DOI: http://doi.org/10.4048/jbc.2012.15.2.218

Abstract

PURPOSE
Patients with recurrent breast cancer usually die of their disease, even after radical surgery and adjuvant therapies which could reduce the odds of dying. Many studies analyzed and compared patients who died of recurrent disease with those that died without recurrent disease. However, less attention has been paid to evaluating factors associated with the timing of recurrence. Thus, the objective of this study is to investigate the correlation between various factors and the timing of recurrence.
METHODS
We retrospectively reviewed the data of 95 recurrent breast cancer patients who underwent curative surgery to determine the prognostic factors such as menopausal status, operation method, stage, nodal status, histologic grade, nuclear grade, extensive intraductal carcinoma component, hormone receptor, p53, c-erbB-2, Ki-67, and molecular subtype. We had attempted to compare the recurrent patients within 2 years after operation and adjuvant chemotherapies as the early recurrence with those over 2 years as the late recurrence.
RESULTS
Histologic grade (p=0.005), nuclear grade (p<0.001), p53 (p=0.022), and Ki-67 (p<0.001) were significant different factors that influenced the systemic recurrence between early recurrence and late recurrence. In stage I/II, histologic grade (p=0.001), nuclear grade (p<0.001), and Ki-67 (p=0.005) were significant factors that influenced the systemic early recurrence. In stage III, nuclear grade (p=0.024), and Ki-67 (p=0.001) were significant factors that influenced the systemic early recurrence. But subtypes (p=0.189, p=0.132, p=0.593, p=0.083) are not associated with the timing of recur rence.
CONCLUSION
In systemic recurrent breast cancer patients, the risk factors such as histologic grade, nuclear grade, p53 and Ki-67 are also associated with the timing of recurrence. We sug gest that these patients should be proper treated and be closely followed up.

Keyword

Breast neoplasms; Recurrence; Risk factors

MeSH Terms

Breast
Breast Neoplasms
Carcinoma, Intraductal, Noninfiltrating
Humans
Recurrence
Retrospective Studies
Risk Factors

Reference

1. Ministry for Health, Welfare and Family Affairs. Annual Report of Cancer Incidence (2007), Cancer Prevalence (2007), and Survival (1993-2007) in Korea. 2009. Seoul: Ministry for Health, Welfare and Family Affairs;14–20.

2. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol. 1995. 13:314–322.

3. Khayat D, Antoine E. Docetaxel in combination chemotherapy for metastatic breast cancer. Semin Oncol. 1997. 24:4 Suppl 13. S13-9–S13-26.

4. Son BH, Ahn SH, Kwak BS, Kim JK, Kim HJ, Hong SJ, et al. The recurrence rate, risk factors and recurrence patterns after surgery in 3,700 patients with operable breast cancer. J Breast Cancer. 2006. 9:134–144.

5. Bland KI, Copeland EM III. Schwartz SI, Shires GT, Spencer FC, editors. Breast. Principles of Surgery. 1994. 6th ed. New York: McGraw-Hill;554–557.

6. Baum M, Badwe RA. Wise L, Johnson H, editors. Does surgery influence the natural history of breast cancer? Breast Cancer: Controversies in Management. 1994. Armonk: Futura Pub.;61–69.

7. Lyman GH, Kuderer NM, Lyman SL, Debus M, Minton S, Balducci L, et al. Survival following early versus late recurrence of breast cancer. 1997. American Society of Clinical Oncology (ASCO) Annual Meeting. 1997. Abstract #633.

8. Kamby C, Vejborg I, Kristensen B, Olsen LO, Mouridsen HT. Metastatic pattern in recurrent breast cancer. Special reference to intrathoracic recurrences. Cancer. 1988. 62:2226–2233.

9. Debonis D, Terz JJ, Eldar S, Hill LR. Survival of patients with metastatic breast cancer diagnosed between 1955 and 1980. J Surg Oncol. 1991. 48:158–163.

10. Pater JL, Mores D, Loeb M. Survival after recurrence of breast cancer. Can Med Assoc J. 1981. 124:1591–1595.

11. Min YK, Kim NR, Cho SJ, Kim A, Bae JW, Koo BH. The clinical significance and prognosis of Korean young age (younger or 35 year old) onset breast cancer. J Korean Breast Cancer Soc. 2001. 4:74–79.

12. Retsky M, Demicheli R, Hrushesky W. Premenopausal status accelerates relapse in node positive breast cancer: hypothesis links angiogenesis, screening controversy. Breast Cancer Res Treat. 2001. 65:217–224.

13. Kute TE, Russell GB, Zbieranski N, Long R, Johnston S, Williams H, et al. Prognostic markers in node-negative breast cancer: a prospective study. Cytometry B Clin Cytom. 2004. 59:24–31.

14. Younes M, Laucirica R. Lack of prognostic significance of histological grade in node-negative invasive breast carcinoma. Clin Cancer Res. 1997. 3:601–604.

15. Noh DY, Han SH, Lee ES, Lee SJ. Korean Breast Cancer Society. The prognostic factors and the predictive factors. The Breast. 1999. Seoul: Ilchokak;388–412.

16. Park SH, Kim SI, Park BW, Lee KS. Prognostic factors in axillary lymph node negative breast cancer. J Korean Breast Cancer Soc. 2004. 7:111–120.

17. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res. 2006. 8:R43.

18. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007. 9:R6.

19. Prati R, Apple SK, He J, Gornbein JA, Chang HR. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. Breast J. 2005. 11:433–439.

20. Bilous M, Ades C, Armes J, Bishop J, Brown R, Cooke B, et al. Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. Breast. 2003. 12:92–98.

21. Riou G, Mathieu MC, Barrois M, Le Bihan ML, Ahomadegbe JC, Bénard J, et al. c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients. Int J Cancer. 2001. 95:266–270.

22. Bianchi S, Palli D, Falchetti M, Saieva C, Masala G, Mancini B, et al. ErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up study. J Cell Physiol. 2006. 206:702–708.

23. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol. 1993. 24:469–476.

24. Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, et al. Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors: a surrogate marker? Cancer. 2003. 97:1321–1331.

25. Pinto AE, André S, Pereira T, Nóbrega S, Soares J. Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma. J Clin Pathol. 2001. 54:543–549.

26. Jung SY, Han W, Shin HJ, Lee JE, Hwang KT, Hwang SE, et al. Usefulness of Ki-67 as a prognostic factor in lymph node-negative breast cancer. J Breast Cancer. 2006. 9:41–46.

27. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006. 295:2492–2502.

28. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007. 13:2329–2334.

29. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007. 13(15 Pt 1):4429–4434.